Navigation Links
ImaginAb Expands Scientific Advisory Board
Date:11/25/2013

LOS ANGELES, Nov. 25, 2013 /PRNewswire/ -- ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody fragment technology, today announced that it has added three new members to its Scientific Advisory Board (SAB). ImaginAb welcomes Dr. Karl Dane Wittrup, Dr. Peter Senter and Dr. Michael Zalutsky, each of whom contributes a history of scientific leadership in a discipline that is fundamental to future applications of ImaginAb's technology.

"The addition of Dr. Wittrup, Dr. Senter and Dr. Zalutsky to the ImaginAb advisory team is an exciting opportunity for ImaginAb to better understand how to position molecular imaging technology to therapeutic areas of growing commercial importance to the company," commented Dr. Anna Wu, ImaginAb's Chief Scientist. "Their expertise in protein engineering, ADC technology and radioimmunoconjugates complements the molecular imaging and mAb platform technology leadership present in our SAB."

Dr. Karl Dane Wittrup, C.P. Dubbs Professor of Chemical Engineering at the Massachusetts Institute of Technology (MIT) and Assoc. Director of the Koch Institute for Integrative Cancer Research has joined ImaginAb's SAB. Dr. Wittrup, a highly recognized thought leader in the field of yeast display, brings tremendous vision and expertise in the field of protein engineering.

Dr. Peter Senter is a pioneer in the field of antibody-drug conjugates (ADCs) and brings tremendous perspective in a field of importance to ImaginAb because of the company's growing focus on building companion diagnostic imaging products for ADC therapeutics.

Dr. Michael Zalutsky is a Professor, Department of Radiology, Radiation Oncology and Biomedical Engineering and Jonathan Spicehandler M.D. Professor of Neuro-Oncology Research at Duke University. The addition of Dr. Zalutsky marks the beginning of a more formal foray into radioimmunoconjugates for therapeutic purposes, including the potential of using alpha-emitting isotopes in conjunction with ImaginAb's minibody platform.

The addition of Drs. Wittrup, Senter and Zalutsky also marks the formal retirement from ImaginAb's SAB of Dr. Steven Larson, the Donna and Benjamin M. Rosen Chair in Radiology at Memorial Sloan-Kettering Cancer Center (MSKCC). Dr. Dan Shochat, formerly Vice President of Development at KaloBios Pharmaceuticals Inc. has joined the management of ImaginAb on a part-time basis as Vice President of Manufacturing and also steps down from ImaginAb's SAB.

Drs. Wittrup, Senter and Zalutsky join founding ImaginAb SAB members Dr. Sanjiv "Sam" Gambhir, Virginia and D.K. Ludwig Professor in Cancer Research, Director Stanford Molecular Imaging Program and Dr. James D. Marks, Professor, Departments of Anesthesia and Pharmaceutical Chemistry, UCSF.

"We welcome these new members to our SAB, but also warmly thank Dr. Larson and Dr. Shochat for their outstanding service to our SAB during the start-up phase of ImaginAb – their advice and continuous challenge of our scientific and commercial assumptions was invaluable," noted Dr. Christian Behrenbruch, CEO of ImaginAb. "We'd particularly like to thank Dr. Larson who has been a driving force in the development of our PSMA minibody technology, currently under clinical investigation at MSKCC."

About ImaginAb

ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging.  The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb's technology is positioned to deliver on the promise of precision medicine by improving patient outcomes and reducing the cost of healthcare. For more information, visit www.imaginab.com.


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Edison expands international biotechnology presence with launch of full coverage of Athersys
2. VolitionRx Expands Sample Size to 11,000 in Pivotal Colorectal Cancer Trial with Hvidovre Hospital, Denmark
3. TransCelerate BioPharma Inc. Launches Second Year Initiatives, Expands Membership and Achieves Milestones for Original Projects
4. ACell Expands Indiana Manufacturing Facility to Support Growth
5. BSMA Expands Advisory Board to Advance BIOTECH SUPPLY CHAIN
6. Annai Systems Expands Access to GTFuse for Rapid and Cost-effective Use of Sequencing Data
7. Digiscribe Expands Document Scanning Services
8. MultiCell Technologies Expands Scope of Research Agreement for the Treatment of Liver Cancer
9. PTC Therapeutics Expands Management Team
10. Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
11. Vince & Associates, Brad Vince Expands Early Phase Gastrointestinal Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2016)... , May 18, 2016 The ... it does not mean that there are no opportunities ahead. ... Pharmaceuticals Inc. (NASDAQ: THLD ), Seattle Genetics Inc. ... CHMA ), and Ophthotech Corp. (NASDAQ: OPHT ). ... alerts at: http://www.activewallst.com/ Threshold ...
(Date:5/18/2016)... ... May 18, 2016 , ... Every day, more than ... asthma complications.* Costing more than $56 billion in direct costs annually, asthma remains ... too many, the suffering associated with uncontrolled asthma can be overwhelmingly disproportionate and ...
(Date:5/18/2016)... ... May 18, 2016 , ... Ryan Benton was diagnosed with Duchenne Muscular Dystrophy ... teens to early twenties. DMD is a relatively common progressive genetic disorder, which causes ... Benton’s condition was critical. He met with the founder of the Stem Cell ...
(Date:5/17/2016)... ... 2016 , ... DryLet, LLC, a biotechnology company providing an ... be showcasing ManureMagic™ at booth V1061 at the World Pork Expo, June 8-10 ... last year and more recently made news as the results were released from ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):